Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)

被引：9

作者：

Luger, Selina M. ^{[1
]}

Sun, Zhuoxin ^{[2
]}

Loghavi, Sanam ^{[3
]}

Lazarus, Hillard M. ^{[4
]}

Rowe, Jacob M. ^{[5
]}

Tallman, Martin S. ^{[6
]}

Pratz, Keith W. ^{[7
]}

Litzow, Mark ^{[8
]}

机构：

[1] Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA

[2] ECOG ACRIN Stat Ctr, Boston, MA USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA

[4] Case Western Reserve Univ, Sch Med, Cleveland, OH USA

[5] Shaare Zedek Med Ctr, Dept Hematol, Jerusalem, Israel

[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[7] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[8] Mayo Clin, Div Hematol, Rochester, MN USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-128377

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1309

引用

页数：4

共 50 条

[21] Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia
Luskin, Marlise R.
DeAngelo, Daniel J.
EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (12) : 1033 - 1045
[22] Midostaurin for Patients With Acute Myeloid Leukemia and FLT3 Mutations
Levis, Mark James
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (06) : 323 - 325
[23] Safety and efficacy of midostaurin in patients with newly diagnosed FLT3-mutated AML
Wang, P-N.
Leung, A. Y. H.
Jang, J. H.
Voloshin, S.
O'Sullivan-Djentuh, L.
Suzuki, K.
Ifrah, S.
Le Gouadec, G.
Kakizume, T.
Kitagawa, H.
Malek, K.
Miyazaki, Y.
ANNALS OF ONCOLOGY, 2018, 29 : 92 - 93
[24] Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy
Wang, Eunice S.
Montesinos, Pau
Minden, Mark D.
Lee, Je-Hwan
Heuser, Michael
Naoe, Tomoki
Chou, Wen-Chien
Laribi, Kamel
Esteve, Jordi
Altman, Jessica K.
Havelange, Violaine
Watson, Anne-Marie
Patkowska, Elzbieta
Liu, Shufang
Wu, Ruishan
Philipose, Nisha
Hill, Jason E.
Gill, Stanley
Rich, Elizabeth Shima
Tiu, Ramon V.
BLOOD, 2021, 138
[25] Cost-Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States
Stein, Eytan M.
Xie, Jipan
Duchesneau, Emilie
Bhattacharyya, Subrata
Ndife, Briana
Bonifacio, Gaetano
Joseph, George J.
BLOOD, 2017, 130
[26] Midostaurin in FLT3-Mutated Acute Myeloid Leukemia REPLY
Stone, Richard M.
Larson, Richard A.
Doehner, Hartmut
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (19): : 1903 - 1903
[27] Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report
Tollkuci, Eris
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (04) : 987 - 989
[28] Neutropenic enterocolitis in patients with FLT3 mutated acute myeloid leukemia undergoing induction chemotherapy with midostaurin
Dotson, Jennifer
Elhamdani, Adee
Petryna, Ellen
Jamil, Muhammad Omer
Alsharedi, Mohamed
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (03) : 351 - 355
[29] FLT3 mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML)
Thiede, Christian
Prior, Thomas W.
Lavorgna, Serena
Krauter, Juergen
Barragan, Eva
Nomdedeu, Josep
Jansen, Joop H.
Wei, Andrew H.
Zhao, Weiqiang
Li, Xiaohong
Pallaud, Celine
Tiecke, Eva
Larson, Richard A.
Bloomfield, Clara D.
Doehner, Hartmut
Ehninger, Gerhard
Stone, Richard M.
Doehner, Konstanze
BLOOD, 2018, 132
[30] Mechanisms of Acquired Resistance to Gilteritinib Therapy in Relapsed and Refractory FLT3 -Mutated Acute Myeloid Leukemia
McMahon, Christine M.
Canaani, Jonathan
Rea, Bryan
Sargent, Rachel Lynn
Morrissette, Jennifer J. D.
Lieberman, David B.
Watt, Christopher
Schwartz, Gregory W.
Faryabi, Robert B.
Ferng, Timothy T.
Shah, Neil P.
Smith, Catherine C.
Carroll, Martin
Perl, Alexander E.
BLOOD, 2017, 130

← 1 2 3 4 5 →